Ping P Chen

US Patent:

6350145, Feb 26, 2002

Filed:

Jan 5, 2000

Appl. No.:

09/477670

Inventors:

Ping Chen - Mundelein IL
Takashi Iida - Anjo, JP

Assignee:

Japan Solderless Terminal Mfg. Co., Ltd. - Osaka-fu

International Classification:

H01R 424

US Classification:

439422, 439877

Abstract:

An FPC crimp terminal comprising a bottom plate being formed from a flat plate and a fixing part rising from an edge of the bottom plate, said FPC crimp terminal being formed in such a way that when a core or a lead wire is brought into direct contact with a conductor of an FPC, the fixing part is made to pierce the FPC from its back or front and the top end of the fixing part coming out of the FPC is bent towards the bottom plate, the core or the lead wire and the FPC will be pinched between the top end of the fixing part and the bottom plate. As the fixing part is used to effect the piercing process and the connecting process at the same time, the FPC crimp terminal can be compactified and the work efficiency can be enhanced through reduction in the number of processes.

US Patent:

6379199, Apr 30, 2002

Filed:

Sep 9, 1999

Appl. No.:

09/392582

Inventors:

Ping Chen - Mundelein IL

Assignee:

Japan Solderless Terminal Mfg. Co., Ltd. - Osaka

International Classification:

H01R 1122

US Classification:

439852, 439451

Abstract:

A female terminal for a connector wherein a leaf spring is provided inside the terminal proper. The front half of the terminal proper is provided with a bottom wall, side walls rising from both ends, in the direction of width, of the bottom wall, an outer upper wall and an inner upper wall extending from the upper edges of side walls to the upper edges of the opposing side walls. A leaf spring is formed by separating said rear inner upper wall from said side walls, with the rear end of said rear inner upper wall being left intact. A bead with a curved section is formed on the leaf spring to increase the flexural rigidity. The female terminal can be compactified, and a sufficient contacting force can be provided reliably. The contacting part of the leaf spring can be shifted forward. The developed shape can be made smaller.

US Patent:

6653304, Nov 25, 2003

Filed:

Feb 8, 2001

Appl. No.:

09/779109

Inventors:

Katerina Leftheris - Skillman NJ
Hong Wu - Lawrenceville NJ
Stephen Wrobleski - Whitehouse Station NJ
Ping Chen - Belle Mead NJ
John Hynes - Washington Crossing PA
John Tokarski - Princeton NJ

Assignee:

Bristol-Myers Squibb Co. - Princeton NJ

International Classification:

C07D40312

US Classification:

5142328, 514292, 544126, 546 81

Abstract:

Use of a compound for treating a respiratory disease in a mammal wherein the compound is a cannabinoid receptor modulator is disclosed. Compounds useful as cannabinoid receptor modulators for treating respiratory and non-respiratory leukocyte-activation associated diseases comprise compounds of formula (I), in which A and B are nitrogen or carbon, provided only one of A and B is nitrogen; and R -R are as defined in the specification, wherein R with R may form a ring, and/or two R groups may form a six-membered aryl or heteroaryl ring, optionally having a substituent R forming a ring with R.

US Patent:

6916809, Jul 12, 2005

Filed:

Dec 20, 2002

Appl. No.:

10/325009

Inventors:

Ping Chen - Belle Mead NJ, US
Edwin J. Iwanowicz - West Windsor NJ, US
Scott H. Watterson - Pennington NJ, US
Henry Gu - Bordentown NJ, US
Yufen Zhao - Pennington NJ, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D471/14
C07D471/04
A61K031/4375
A61P019/02
A61P017/06

US Classification:

5142305, 51425505, 514256, 514293, 544105, 544333, 544405, 544 60, 544126, 544361, 544250, 546 81, 540575

Abstract:

Compounds having the formula (I), wherein Ris selected from H, OH and NH; Ris selected from ═O and ═S; W is —C(═O)—, —S(═O)—, or —S(O)—; or W may be —CH— if X is —C(═O)—; X is selected from —CH—, —N(R)—, and —O—, except that when W is —CH—, X is —C(═O)—; Y is a bond or —C(R)(R)—; Q is a linker; Z is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl; and X, X, X, X, X, X, X, X, X, Xand Xare selected such a tricyclic heteroaryl ring system is formed as further defined in the specification.

US Patent:

7064203, Jun 20, 2006

Filed:

Dec 22, 2004

Appl. No.:

11/019899

Inventors:

Ashvinikumar V. Gavai - Princeton Junction NJ, US
Wen-Ching Han - Newtown PA, US
Ping Chen - Belle Mead NJ, US
Edward H. Ruediger - Greenfield Park, CA
Harold Mastalerz - Guilford CT, US
Brian E. Fink - Princeton Junction NJ, US
Derek J. Norris - Pennington NJ, US

Assignee:

Bristol Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
A61K 31/53
A61P 19/02

US Classification:

544183, 514243

Abstract:

The present invention provides compounds of formula IThe compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

US Patent:

7141571, Nov 28, 2006

Filed:

Dec 22, 2004

Appl. No.:

11/019901

Inventors:

Brian E. Fink - Princeton Junction NJ, US
Ashvinikumar V. Gavai - Princeton Junction NJ, US
Gregory D. Vite - Titusville NJ, US
Ping Chen - Belle Mead NJ, US
Harold Mastalerz - Guilford CT, US
Derek J. Norris - Pennington NJ, US
John S. Tokarski - Princeton NJ, US
Yufen Zhao - Pennington NJ, US
Wen-Ching Han - Newton PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
A61K 31/53

US Classification:

514243, 544183

Abstract:

The present invention provides compounds of formula IThe formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

US Patent:

7151176, Dec 19, 2006

Filed:

Oct 19, 2005

Appl. No.:

11/253832

Inventors:

Ashvinikumar V. Gavai - Princeton Junction NJ, US
Wen-Ching Han - Newtown PA, US
Yufen Zhao - Pennington NJ, US
Ping Chen - Belle Mead NJ, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
A61K 31/53
A61P 19/02
A61P 35/00

US Classification:

544183, 514243

Abstract:

The present invention provides compounds of formula IThe compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

US Patent:

7297695, Nov 20, 2007

Filed:

Jun 26, 2006

Appl. No.:

11/426479

Inventors:

Brian E. Fink - Princeton Junction NJ, US
Ashvinikumar V. Gavai - Princeton Junction NJ, US
Gregory D. Vite - Titusville NJ, US
Ping Chen - Belle Mead NJ, US
Harold Mastalerz - Guilford CT, US
Derek J. Norris - Pennington NJ, US
John S. Tokarski - Princeton NJ, US
Yufen Zhao - Pennington NJ, US
Wen-Ching Han - Newtown PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
C07D 401/06
C07D 401/14
A61K 31/53
A61P 35/00

US Classification:

514243, 544183

Abstract:

The present invention provides compounds of formula IThe formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.